

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10517784
	Filing Date		2004-12-13
	First Named Inventor	Gideon Gross	
	Art Unit	1643	
	Examiner Name	RAWLINGS, STEPHEN L	
	Attorney Docket Number	GROSS32	

1 / 4

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7414108	B2	2009-08-19	LAUS, REINER ET AL	
	2	6210662	B2	2001-04-03	LAUS, REINER ET AL	
	3	6194152	B1	2001-02-27	LAUS, REINER ET AL	
	4	6080409	A	2000-06-27	LAUS, REINER ET AL	
	5	5976546	A	1999-11-02	LAUS, REINER ET AL	
	6	7718762	B2	2010-05-18	COGGIN Jr., JOSEPH H. ET AL	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add
U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10517784
Filing Date	2004-12-13
First Named Inventor	Gideon Gross
Art Unit	1643
Examiner Name	RAWLINGS, STEPHEN L
Attorney Docket Number	GROSS32

2 / 4

1						
---	--	--	--	--	--	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² ;	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	YU YIKY L et al., "Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells." Journal of Immunology 168: pages 3145-9 (2002);	<input type="checkbox"/>
	2	VAN DEN EYNDE BJ et al. "T cell defined tumor antigens" Current Opinion in Immunology Current Biology Ltd 9: pages 684-93 (1997);	<input type="checkbox"/>
	3	TAFURO et al. "Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2M fusion molecules" European Journal of Immunology 31: pages 440-9 (2001);	<input type="checkbox"/>
	4	WEN Y J et al. " Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma." British Journal of Haematology 100: pages 464-8 (1998);	<input type="checkbox"/>
	5	JAMES L GULLEY et al. "Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer." Cancer Immunol Immunother 59: pages 663-674 (2010);	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10517784
Filing Date	2004-12-13
First Named Inventor	Gideon Gross
Art Unit	1643
Examiner Name	RAWLINGS, STEPHEN L
Attorney Docket Number	GROSS32

3/4

6	SONIA.E PEREZ et al."A New Era in Anticancer Peptide Vaccines" Cancer 116: pages 2071-2080 (2010);	<input type="checkbox"/>
7	TAYLOR H. SCHREIBER et al. "Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art" Seminars in Immunology 22: pages 105–112 (2010);	<input type="checkbox"/>
8	MICHAL J. BESSER et al, "Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients" Clinical Cancer Research 16 (9): pages 2646-2655 (2010);	<input type="checkbox"/>
9	ERIC J. SMALL et al, "Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer" Journal of Clinical Oncology 24 (10): pages 3089-3094 (2006);	<input type="checkbox"/>
10	BONNIE TAYLOR-BLAKE et al, "Prostatic Acid Phosphatase Is Expressed in Peptidergic and Nonpeptidergic Nociceptive Neurons of Mice and Rats" PLoS ONE 5 (1): pages 1-5 (2010);	<input type="checkbox"/>
11	MARK J. ZYLKA et al, "Prostatic Acid Phosphatase Is an Ectonucleotidase and Suppresses Pain by Generating Adenosine" Neuron 60: pages 111-122 (2008);	<input type="checkbox"/>
12	"Sipuleucel-T: APC 8015, APC-8015, Prostate Cancer Vaccine – Dendreon" [No authors listed] Drugs in R&D 7 (3): pages. 197-201 (2006).	<input type="checkbox"/>
13	PAMER and CRESSWELL, Mechanisms of MHC Class I-Restricted Antigen Processing, Annu. Rev. Immunol., 16:323-58 (1998)	<input type="checkbox"/>
14	MARRACK et al., Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction, Annu. Rev. Immunol., 26:171-203 (2008)	<input type="checkbox"/>
15	MATSUI et al., Kinetics of T-cell Receptor Binding to Peptide/I-Ek Complexes: Correlation of the Dissociation Rate with T-Cell Responsiveness, Proc. Natl. Acad. Sci. USA, 91:12862-12866 (1994)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10517784
Filing Date	2004-12-13
First Named Inventor	Gideon Gross
Art Unit	1643
Examiner Name	RAWLINGS, STEPHEN L
Attorney Docket Number	GROSS32

4 / 4

EXAMINER SIGNATURE

Examiner Signature	/Stephen Rawlings/	Date Considered	10/25/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.